Medicines access group takes aim at Sovaldi patents

7 December 2017

Two new patent challenges have been launched by the New York-based patient access and public health activist I-MAK - the Initiative for Medicines, Access & Knowledge.

The actions are being taken against sofosbuvir-based products. Sofosbuvir is the generic name for HCV drug Sovaldi.

These challenges, which build on previous legal bids that the group filed against six sofosbuvir patents in October, are based on patents which relate to particular mixtures of active and inactive ingredients, a practice I-MAK describes as a “classic case of how pharmaceutical companies try to extend their patent exclusivity.”

I-MAK says that if it is successful in overturning the eight patents held by California’s Gilead Sciences (Nasdaq: GILD), then US taxpayers would save more than $10 billion as a result of generics coming to market 16 years sooner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK